Fig. 7: Protective effect of ARO112 against colitis in DSS-treated mice.
a Experimental setup of IBD mouse model Nod2−/− mice treated with DSS, and treated with ARO112 or PBS (Ctrl). b Disease activity index obtained by the sum of weight loss subscore, stool consistency subscore and bleeding subscore (see Supplementary Data 6; two-sided Mixed-effect analysis with Sidak correction for multiple comparisons. c Mouse body weight loss during experiment and d at days 4 and 7. Four of six mice from control group (Ctrl) were euthanized after reaching a disease activity index of 12. e Survival curve showing percentage of mice that were euthanized due to reaching the experimental endpoint (disease activity index of 12; Log-rank (Mantel-Cox) test; *p < 0.05). f Colon length of mice euthanized upon reaching the experimental endpoint or sacrificed at the end of the experiment (two-tailed Mann-Whitney test; *p < 0.05). g Histological score obtained from the colon of animals (two-sided Mixed-effect analysis with Sidak correction for multiple comparisons; **p < 0.01). h Fecal lipocalin-2/NGAL levels measured throughout the experiment (two-sided Mixed-effect analysis with Sidak correction for multiple comparisons; **p < 0.01). This experiment was performed in 6 mice per group in two independent experiments (n = 3 per group per experiment). Panel a was adapted from a figure created in BioRender. Oliveira, R. (2025) https://BioRender.com/i1ikv6t.
